Neurogene Inc.

Healthcare · Biotechnology · United States

Last price 28.82 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 576.73M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The comp...